Cuba vs Niger: HIV/AIDS deaths averted by antiretroviral therapy
Cuba
1,468 deaths
in 2024
Niger
1,361 deaths
in 2024
Cuba rank
65th
Niger rank
67th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Cuba
- Niger
How they compare
Cuba currently reports 1,468 deaths against 1,361 deaths in Niger, a difference of 107 deaths.
That makes Cuba's figure about 1.1 times Niger's.
The two have swapped places 5 times across 35 shared years of data; in 1990 it was Niger ahead.
Cuba ranks 65th and Niger ranks 67th of 157 countries.
Across the 4 decades both report, Cuba averaged higher in 2 and Niger in 1.
Head to head by decade
| Decade | Cuba | Niger | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 292.14 deaths | 290.37 deaths | 1.78 deaths | Cuba |
| 2010s | 1,136 deaths | 1,440 deaths | 303.5 deaths | Niger |
| 2020s | 1,525 deaths | 1,431 deaths | 94.02 deaths | Cuba |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Cuba or Niger?
- Cuba, at 1,468 deaths against 1,361 deaths in Niger as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Cuba and Niger?
- 107 deaths, with Cuba ahead.
- How many years of comparable data are there for Cuba and Niger?
- 35 years are reported by both, from 1990 to 2024.
- How do Cuba and Niger rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Cuba ranks 65th and Niger ranks 67th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.